Acadia History
For decades, we have turned scientific promise into meaningful innovations—reimagining care for patients, putting unmet needs first, and expanding possibilities for families impacted by neurological disorders and rare diseases.
Acadia Does Things Differently
Advancing new therapies in neurological disorders and rare disease is complex, the path forward isn't always obvious, and bringing therapies to market is challenging. It's easy to be cynical. But at Acadia, we believe that the effect of saying no is too great to ignore. We're committed to underserved patients and families. We see opportunity where others see reasons to stop.
2025
Acadia submits its first Marketing Authorization Application (MAA) to the European Medicines Agency for trofinetide to treat Rett syndrome.
Acadia hosts its inaugural R&D Day, showcasing key pipeline programs and long-term growth drivers as part of the company’s strategy for sustained growth.
2024
Health Canada approves DAYBUE® (trofinetide) for the treatment of Rett syndrome, expanding the drug’s availability beyond the United States.
Acadia enters an exclusive licensing agreement with Saniona AB for a Phase 2 essential tremor drug candidate.
2023
FDA approves DAYBUE® (trofinetide) as the first therapy for Rett syndrome in adults and children two years of age and older.
Acadia acquires ex–North American rights to trofinetide and global rights to Neuren’s NNZ-2591, expanding its Rett syndrome and Fragile X syndrome pipeline.
2022
Acadia and Stoke Therapeutics enter a strategic collaboration to develop multiple RNA-based therapies for rare genetic neurodevelopmental diseases.
2021
Acadia announces positive Phase 3 results from the LAVENDER™ study of trofinetide in Rett syndrome, paving the way for regulatory submission.
2020
Acadia enters an exclusive license and research collaboration with Vanderbilt University to develop novel therapies for central nervous system disorders.
Acadia and Neuren announce Rare Pediatric Disease (RPD) Designation for trofinetide as a potential Rett syndrome treatment.
Acadia acquires CerSci Therapeutics.
2018
Acadia secures exclusive North American rights to trofinetide from Neuren Pharmaceuticals for development and commercialization in Rett syndrome.
2017
Acadia is named one of Forbes’ “Most Innovative Growth Companies,” ranking #11 of 100.
2016
FDA approves NUPLAZID® (pimavanserin), the first treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
2014
FDA grants Breakthrough Therapy Designation to NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Acadia Pharmaceuticals GmbH (European subsidiary) is established.
2012
Acadia reports positive Phase 3 trial results for pimavanserin in patients with Parkinson’s disease psychosis.
2010
Acadia initiates a Phase 3 study of pimavanserin in Parkinson’s disease psychosis.
2004
Acadia completes its initial public offering (IPO) and begins trading on the NASDAQ Stock Market under the symbol “ACAD.”
1999
Acadia begins research into a new non-dopaminergic antipsychotic agent selectively acting as inverse agonists on the 5-HT2A receptor.
1997
Company rebrands as Acadia Pharmaceuticals Inc., inspired by Acadia National Park, and relocates its headquarters from Vermont to San Diego, California.
1993
Acadia Pharmaceuticals was founded (as Receptor Technologies) by University of Vermont professor, Mark Brann, Ph.D.
Important Disclosures
- The safety and efficacy of the investigational agent(s) listed above have not been established or approved by the U.S. Food and Drug Administration (FDA).
- Please read the full Prescribing Information, including Boxed WARNING, for NUPLAZID® (pimavanserin)
- Please read the full Prescribing Information, for DAYBUE® (trofinetide)